Transcatheter ablation (TA) for treatment of pediatric tachyarrhythmias was first introduced in
the early 1990s. Since then, its use as an alternative to antiarrhythmic drugs to treat
supraventricular tachycardias (SVTs) caused by accessory pathway (AP) has been
gradually increasing, to the point that nowadays TA can be performed with high success
rates and low complication rates. Moreover, recently, the use of different types of energy
(radiofrequency [RF] and cryoenergy), special ablation catheters, and 3-dimensional (3D) …